pre-update Archives

On-Demand Webinar

RAPS sponsored webcast: The EU Clinical Trials Regulation – Challenges Drug Developers Faced in the First 6 months

Join us on November 10th for this webcast being held in partnership with RAPS. The…

CertaraOctober 17, 2022

Blog

PBPK Modeling & Simulation of Therapeutic Oligonucleotides from Bench to Bedside

Next generation therapeutics Oligonucleotide drugs are unique among therapeutic modalities in that they don’t engage…

CertaraOctober 14, 2022

Fact Sheet

PK Submit™ Overview

Learn how PK Submit accelerates NCA workflows and ensures regulatory compliance.

CertaraOctober 12, 2022

Announcement

Certara Announces New Release of PK Submit

PRINCETON, N.J.— October 12, 2022 – Certara, Inc., a global leader in drug development software,…

CertaraOctober 12, 2022

On-Demand Webinar

How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing

Historically, the dosing strategy for oncology drugs focused on the maximum tolerated dose. This has…

CertaraOctober 5, 2022

Blog

Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist

Choosing the right technology and services vendor to support your organization’s transparency and disclosure (T&D)…

CertaraOctober 4, 2022

Blog

5 Steps to Satisfy New EU-CTR Requirements for Plain Language Summaries of Clinical Study Results

For the first time, the European Medicines Agency (EMA) has passed new regulations to help…

CertaraSeptember 27, 2022

Business transparency, integrity or data disclosure concept, businessman standing with disclosure financial document in crystal clear fish bowl

Blog

EU-CTR Challenges Drug Developers Faced in the First 6 Months

Under European Union Clinical Trial Regulation 536/2014 (EU-CTR), replacing the EU Clinical Trial Directive (Directive…

CertaraSeptember 26, 2022

Podcast

Certara – Improving Investment in Drug Development through Biosimulation

CertaraSeptember 23, 2022

On-Demand Webinar

Optimize drug development with public data and predictive models – model-based meta-analysis (MBMA)

Properly understanding the probability of successful drug development requires utilization of all available information. Critical…

CertaraSeptember 23, 2022

pre-update

RAPS sponsored webcast: The EU Clinical Trials Regulation – Challenges Drug Developers Faced in the First 6 months

PBPK Modeling & Simulation of Therapeutic Oligonucleotides from Bench to Bedside

PK Submit™ Overview

Certara Announces New Release of PK Submit

How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing

Choosing a Clinical Trial Transparency and Disclosure Vendor: Your Complete Checklist

5 Steps to Satisfy New EU-CTR Requirements for Plain Language Summaries of Clinical Study Results

EU-CTR Challenges Drug Developers Faced in the First 6 Months

Certara – Improving Investment in Drug Development through Biosimulation

Optimize drug development with public data and predictive models – model-based meta-analysis (MBMA)

Newsletter sign up

Quick links

Solutions

Contact